中文版
|
English
Hotline：+86 2864841719
Enlai News
Enlai News
CONTACT US
联系我们
Outbound sales&marketing
Contact：Mr. Yang
Tel：+86-28-84871826
Mobile：+86 13908183771
Email：sealinfa@enlaibio.com

Outbound sales&marketing
Contact：Manager Tang
Mobile：+86 18054780191
Email：Amy@enlaibio.com

Outbound sales&marketing
Contact：Manager Yi
Tel：+86-28-84841969
          18980456393
Mobile：+86 18728045915
Email：nero@enlaibio.com

Outbound sales&marketing
Contact：Manager Jiang
Tel：+86-28-64841719
Mobile：+86 17390183901
Email：cynthia@enlaibio.com

Industry News Your current location:Homepage >Industry News
请添加图片
First line treatment for chronic lymphocytic leukemia

As a first line treatment drugs for chronic lymphocytic leukemia, Ibrutinib improves survival compared with Ofatumumab in patients with previously treated Chronic Lymphocytic Leukemia.

From Poverty to Harvard Postdoc2013-10-24

Fingerprints Expose Chemical Identities 2019-01-04

2019 CPHI Shanghai Bio-Pharm Expo 2019-08-18


Outbound Sales&Marketing

Contact：Mr. Yang  Tel：+86-28-84871826  Mobile：+86 13908183771  Email：sealinfa@enlaibio.com
Contact：Manager Tang  Mobile：+86 18054780191  Email：Amy@enlaibio.com
Contact：Manager Yi  Tel：+86-28-84841969  18980456393  Mobile：+86 18728045915  Email：nero@enlaibio.com
Contact：Manager Jiang  Tel：+86-28-64841719  Mobile：+86 17390183901  Email：cynthia@enlaibio.com
友情链接：

扫码二维码
打开官方网站

扫码二维码
关注官方微信
蜀ICP备10203788号